OSCR vs CLOV

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 13, 2026

OSCR

54.6
AI Score
VS
OSCR Wins

CLOV

36.9
AI Score

Investment Advisor Scores

OSCR

55score
Recommendation
BUY

CLOV

37score
Recommendation
AVOID NEW MONEY

AI Analyst Insights

Detailed Metrics Comparison

Metric OSCR CLOV Winner
Forward P/E 588.2353 37.7358 CLOV
PEG Ratio 0 0 Tie
Revenue Growth 72.1% 53.1% OSCR
Earnings Growth 125.6% 0.0% OSCR
Tradestie Score 54.6/100 36.9/100 OSCR
Profit Margin 4.9% 0.4% OSCR
Beta 1.00 1.00 Tie
AI Recommendation BUY AVOID NEW MONEY OSCR

Relative Price Performance (Last 90 Days)

OSCR 1M: -7.2% · 3M: -1.6% CLOV 1M: +6.0% · 3M: +16.2%

Current Technical Phase

OSCR

Neutral
Hold

Mixed signals - no dominant trend phase, RSI 47

RSI (14): 46.5 · Price: $31.05

CLOV

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (3.3% over 20 days), RSI 59

RSI (14): 58.5 · Price: $4.96

Fundamentals Snapshot

Metric OSCR CLOV
Market Cap — —
Forward P/E 12.7 27.6
Trailing P/E 14.2 488.0
Revenue (TTM) — —
Revenue Growth 0.7% 0.5%
Gross Margin 0.2% 0.2%
Operating Margin 0.1% 0.0%
EPS 2.25 0.01
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, OSCR is currently the stronger investment candidate based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.